Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-07-26 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
FORM 3 -
Director's Dealing
2016-07-26 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-07-26 English
FORM 4 -
Director's Dealing
2016-07-22 English
FORM 4 -
Director's Dealing
2016-07-22 English
FORM 4 -
Director's Dealing
2016-07-22 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 21, 2016, reporting multiple significant corporate events. It details the completion of a merger, a reverse stock split, a name change, issuance of shares, changes in the board of directors and senior management, dismissal of the independent auditor, and other related corporate governance matters. The presence of sections such as Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.02 (Unregistered Sales of Equity Securities), Item 3.03 (Material Modification to Rights of Security Holders), Item 4.01 (Change in Registrant's Certifying Accountant), Item 5.01 (Changes in Control of Registrant), and Item 5.02 (Departure and Appointment of Directors and Officers) indicates this is a current report disclosing material corporate events and management changes. The document is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is not a simple announcement of a report but a detailed regulatory filing reporting significant corporate events. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-07-22 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.